Population Pharmacokinetics of Oxcarbazepine: A Systematic Review

Yue-ting Chen 1,2#, Chen-yu Wang 1#, Yi-wei Yin 1#, Zi-ran Li 3; Wei-wei Lin 4; Min Zhu 1,2; Zheng Jiao 1*

1 Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China;
2 School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China;
3 Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China;
4 Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Yue-ting Chen, Chen-yu Wang and Yi-wei Yin contributed equally to this work.

*Corresponding author:
Zheng Jiao, Professor
Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University
241 Huaihai West Road, Shanghai, China, 200030
Tel.: +86 (21) 2220 0000 ext 3021
E-mail: jiaozhen@online.sh.cn;
ORCID: Zheng Jiao: https://orcid.org/0000-0001-7999-7162

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

Introduction: Oxcarbazepine is commonly used as a first-line drug in the treatment of partial seizures. Due to the high pharmacokinetic variability of oxcarbazepine, many population pharmacokinetic models have been developed to optimise the dosing regimen of oxcarbazepine.

Areas covered: This review summarize the published population pharmacokinetic studies of oxcarbazepine in children and adults. The quality of the identified reports from the PubMed and Embase databases was also evaluated. We also explored the significant covariates that may have an impact on the dosage regimen and clinical use of oxcarbazepine.

Expert Opinion: The oxcarbazepine dose regimen was dependent on weight and co-administration with enzyme-inducing medications. In order to achieve more accurate treatment, we should establish PK / PD model of OXC to evaluate the effectiveness of dose adjustment from pharmacodynamic indicators. Furthermore, exploring the pharmacokinetic in specifical patients, such as infants is essential to improve its safety.

Keywords: Epilepsy; Nonlinear mixed effect modelling; Oxcarbazepine; Population pharmacokinetic;
**Article highlights**

- In this review, we identified weight, renal function, and co-administered medications as covariates that most likely to influence oxcarbazepine pharmacokinetics.

- Comparing to adult patients, paediatric patients show a higher clearance per kilogramme weigh which lead to higher doses per kilogramme; they may also require therapeutic drug monitoring owing to a larger variation in clearance.

- Further studies are essential to evaluate oxcarbazepine pharmacokinetics in special populations such as infants.
1. Introduction

Oxcarbazepine (OXC) is a commonly used anti-epilepsy drug with a chemical structure similar to carbamazepine (CBZ) [1]. It was approved by the Food and Drug Administration as a monotherapy and adjunctive therapy for partial seizures in adult and paediatric patients. It prevents seizures mainly through the blockage of voltage-dependent sodium channels, similar to CBZ [2]. Owing to its comparable effectiveness but better safety and tolerability, OXC is usually used as an alternative to CBZ in patients who are unable to tolerate CBZ [3,4].

Oxcarbazepine is completely absorbed (>95%) and quickly transformed to its active metabolite 10-hydroxycarbazepine (MHD) by cytosolic enzymes after oral administration [5,6]. Owing to its rapid metabolism, OXC has a much lower area under the concentration-time curve (AUC) than MHD in vivo (16.05 vs. 215.52 μg·h/ml) [7]. Thus, the effectiveness of OXC is mainly determined by measuring MHD concentration [8]. Following OXC administration, the concentration of MHD reaches a peak in approximately 2–4 h [9]. MHD has a low protein binding rate (~39%) [10], and its volume of distribution (Vd) is between 0.3 and 0.8 L/kg [6]. MHD is excreted unchanged in the urine or eliminated in conjugation with uridine diphosphate-glucuronosyltransferase (UGT), with only a small fraction (4%) being oxidised to its dihydroxy derivative (DHD) [5,11].

In special patient populations, such as patients with renal insufficiency, patients who are co-administered OXC with enzyme-inducing antiepileptic drugs (EIAEDs) as well as the elderly and infants, the pharmacokinetics (PK) of MHD varies greatly [12].
Rouan et al. [12] reported that the mean $\text{AUC}_{0-168\ h}$ of MHD in patients with severe renal impairment was around 2–2.5 times higher than that in healthy subjects after receiving a single oral dose of OXC. A high exposure to OXC is associated with an increased incidence of side effects [13]; therefore, to ensure effectiveness and safety, therapeutic drug monitoring (TDM) is essential for patient-specific dose adjustment [14]. Ideally, individualised doses need to be developed at the beginning of treatment; however, the current TDM approach is usually implemented during the course of the treatment. The population pharmacokinetic (PPK) approach has been used to identify significant covariates that influence PK and is often used in clinical practice through Bayesian forecasting to develop individualised therapy at the beginning and even during the course of treatment [15,16].

Despite the reports of PPK study are numerous, no research has been conducted to review the PPK of MHD. Analysing and understanding the significant covariates and their relationship in different patient populations is critical for the development of appropriate regimens for individualised therapy. In this review, we aim to summarise the significant covariates affecting PK, identify unexplored covariates, and provide evidence for the model informed of OXC.

2. Methods

2.1 Search Strategy

The PubMed and Embase databases were used to systematically search for articles on PPK of OXC published before 31 October 2020 followed the principles of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)
The search terms used included “oxcarbazepine”, “oxcarbamazepine”, “ocbz”, “oxtellar”, or “trileptal” and “population pharmacokinetic”,”pharmacokinetic modeling”, “nonlinear mixed effect model”, “NONMEM”, “Pmetrics”, “WINNONMIX”, “ADAPT”, “P-PHARM”, “nlmixed”, “NLME”, “USC*PACK”, or “MONOLIX”. Besides, references of all included studies were searched.

All the relevant articles selected from the databases and reference lists were screened to evaluate their eligibility for inclusion according to the following criteria:
1. target group of studies was human; OXC was the study drug; PPK analysis was conducted in the study; and the study was published in English. A study was excluded if it was a review or external evaluation article; the data presented overlapped with previous studies but with smaller sample sizes; or the PK parameters were incomplete.

Two independent authors screened the title and abstracts as well as the full-text of each article to determine their eligibility. Discrepancies were resolved by a third senior investigator.

2.2 Evaluation of Literature Quality

The quality of the PPK report was evaluated according to previous guidelines of PK reports (Kanji et al. [17] and Jamsen et al. [18]) that assist in transparent and complete reporting. A checklist with 24 items was developed to summarise the key points of the report. All items were categorised into five sections: the title and abstract, background and introduction, methods, results, and discussion and conclusion, according to their relevance to the sections of the research report.

If there was a description in the paper that conforms to the criterion, the scoring
item will be counted as 1 point. If it was not reported, zero points were given. Each
identified study was evaluated based on these criteria. Compliance of the included
PPK studies was reported as a proportion. The compliance rate was calculated as
follows:

\[
\text{compliance rate (\%)} = \frac{\text{sum of reported items}}{\text{sum of all items}} \times 100\%
\]

2.3 Data Extraction

A standardised data collection was used to extract the relevant information from
each eligible study as follows: patient characteristics, such as age, weight, and
laboratory test, ; the study design, such as research types, quantity of subjects and
observations; dose regimens; OXC formulation; and PPK study information such as
data analysis software and algorithm, model strategies, final PK parameters, and
tested and significant covariates.

2.4 Study Comparison

We developed virtual patients with different age: infants (10 kg, 1-year-old) taking
300 mg OXC every 12 h (q12h), children (30 kg, 10 years old) taking 300 mg OXC
q12h, and adults (70 kg, 40 years old) taking 600 mg OXC q12h. The
concentration–time profiles in virtual patients were drew on the basis of the restored
PPK model and study population in each included study. They received multiple
doses of OXC alone and achieve stable state. The sex of the virtual patient was
selected as male.

The identified covariates effect on clearance (CL) in the included studies was
analysed and showed by a forest map. The CL change less than between 80%-125%
was not considered to have a significant clinical correlation [19]. For binary
covariates such as co-administration with medications, we use 0 for monotherapy and
1 for co-administration with medications. For continuous covariates that were
included in only one model, we used the same range values as the study. For
continuous covariates included in multiple studies, we scaled them to the same range
for comparison. The effect of each covariate on CL was shown as the ratio of CL in
the range of the covariate divided by the typical CL value in each study.

The simulation was conducted using NONMEM (version 7.4; ICON Development
Solutions, Ellicott City, MD, USA) software. R (version 3.5.1;
http://www.r-project.org/) was used to generate the concentration–time plots and
forest plots.

3. Results

3.1 Study Identification

A total of 155 articles were selected: 87 articles were selected from PubMed; 67
articles from the Embase database; and one article from the references of selected
articles. After initial screening, 16 full-text studies were assessed for eligibility. One
study was excluded because the final PK parameters were not presented [20], and two
were excluded because of language [21,22]. In addition, the study conducted by Sallas
et al. [23] was excluded because the study data overlapped with that of Sugiyama et al.
[24]. Finally, 12 articles were included in the study (Fig. 1).

3.2 Evaluation of Literature Quality

According to the guidelines, we summarised the quality of OXC PPK studies based
on 35 items, as outlined in Table 1. Compared with that of the PPK articles published between 2005 and 2013, the quality of PPK studies published between 2014 and 2019 significantly improved [compliance rate median (range): 71.4% (68.6%–71.4%) vs. 94.3% (85.7%–97.1%)]. Generally, prospective studies show better compliance than retrospective studies; however, the prospective study by Northam et al. [25] had a compliance rate of only 73.5%. This may be due to the lack of a standard reporting guide published at that time.

After the guidelines were published, the quality of PPK study reports improved over time. Nonetheless, several studies still have compliance rate of less than 60%, which included deficiencies in the description of sample, statistical methods and software, and methods for handling missing data.

### 3.3 Study Characteristics

The included studies were published from 2005 to 2019. The total quantity of subjects in included articles between 12 and 573. Most PPK analysis was performed in patients with epilepsy [24,26-33], and only Antunes et al. [34] enrolled healthy subjects. One study was conducted only in infants [25], seven studies were conducted in children [24,25,27,28,30-32], two studies included both children and adults [26,33], and two studies only enrolled adults [29,34]. Subjects in all the included studies were administered OXC orally, with doses ranging from 75 to 1800 mg/d. In most studies, sparse sampling was employed, with 1 to 4 samples collected per individual. Detailed characteristics of all included studies were listed in Table 1.

The PPK analyses were all conducted using population modelling software,
including NONMEM (Icon, Dublin, Ireland) [24-26,29-31,34,35], Phoenix NLME (Certara L.P. Pharsight, St. Louis, MO, USA) [26–28], and Monolix (Lixoft, Antony, France) [32]. The most commonly used algorithm was first-order conditional estimation with the $\eta$-$\epsilon$ interaction.

Most studies described the PK of MHD as a one-compartment model with first-order absorption and elimination. Rodrigues et al. [32] described the PK of OXC and its active metabolite MHD with a two-compartment model with first-order absorption and elimination. Antunes et al. [34] described the PK of OXC and its active metabolite enantiomers using a two-compartment model with transit absorption and first-order elimination.

All studies used either internal or external evaluation. The commonly method of external evaluation is the goodness-of-fit plot, while the second popular method was the visual predictive check. Although a normalised prediction distribution error (NPDE) has better properties [36], it is not commonly used [29,30,32,34]. Four studies performed an external evaluation using an independent dataset, all of which showed acceptable predictability [28,30,31,33].

3.4 Study Comparison

There were no obvious differences in the PK of OXC due to ethnicity. Fig. 2 shows concentration-time profiles of all studies that are simulated with virtual infant (a), children (b) and adult (c) patients. The model established by Peng et al. [27] which presented lower CL, displayed a much higher trough concentration ($C_{\text{trough}}$) than others (CL: 0.016 vs. 0.035–0.073 L/h/kg). On the contrary, the PPK model
established by Yu et al. [33] which presented a higher CL, showed a considerably lower \( C_{\text{trough}} \) than others (CL: 0.084 vs. 0.035–0.073 L/h/kg).

The estimated median CL was 0.078 L/h/kg for infants (10 kg, 1 year) [25], 0.058 (range: 0.016–0.084) L/h/kg for children (30 kg, 10 years) [24,26-28,30-33], and 0.033 (range: 0.029–0.0599) L/h/kg for adults (70 kg, 40 years) [26,29,33-35]. The median CL per kg in infants and children was higher than that in adults. Furthermore, children had a larger variability in CL than adults (0.016–0.084 L/h/kg vs. 0.029–0.06 L/h/kg).

Moreover, the median Vd per kg in infants and children was higher than that in adults. The determined median Vd was 1.38 L/kg for infants, 0.78 (range: 0.47–2.16) L/kg for children, and 0.45 (range: 0.2–1.48) L/kg for adults.

The final PK parameters included in our review are summarised in Table 3. The between-subject variability (BSV) was determined from exponential models in all included studies. The median (range) BSV was as follows: CL, 16.84% (11.09%–34.21%); Vd, 35.35% (6.88%–104.4%); and Ka, 24.05% (8.27%–39.82%). The residual unexplained variability (RUV) was described using the proportional model: 12.05% (4%–32%) or additive model: 3.396 mg/L (0.93–0.512 mg/L).

All PPK analysis intended to explain the BSV of MHD PK by investigating possible covariates. The covariates investigated and identified in each study are visually shown in Fig. 3. The commonly investigated covariates included weight, sex, age, co-administered medications, body surface area, and estimated glomerular filtration rate (eGFR). The identified covariates for CL included weight,
co-administered medications, eGFR, dose. All the investigated and identified
covariates in the PPK model are summarised in Table S1.

It was found that eGFR significantly affected MHD CL, according to the
observations from Lin et al. [29]. In patients with impaired renal function (eGFR:
20–80 mL/min), the CL was 34.8% (9.4%–64.2%) lower than those with normal renal
function.

There was one study identified dose could affect CL, which may indicate a
nonlinear elimination of MHD [27]. However, these effects may on account of the
dose adjustment in clinical practice according to the TDM process, which can be
misinterpreted as nonlinearity in the system [37]. Therefore, further in-depth study on
the possible PK of MHD is necessary.

The influence of all included covariates on CL is shown in Fig. 4. The ranges of
continuous covariates that were scaled are as follows: the weight of adults was set at
40–100 kg and that of children was set at 16–40 kg. The age was set as 18–75 years.
The range of eGFR and alanine aminotransferase (ALT) were set as 20–120 mL/min
and 5–150 U/L, respectively. The dose of OXC was set as 75–1350 mg/kg/d.

Ten of all studies that investigated impact of the weight indicated that it was
associated with the CL of MHD [24,26-32,34,35]. Weight had a significant influence
on CL. Our finding showed that the CL of patients with different weight could range
from 0.54 to 1.8 times compared to the typical patient (children: 30kg, adults: 70kg).
Co-administration with EIAEDs also significantly affected CL in children and adults,
which approximately increased 1.17 to 1.63 times [24-26,28,32]; in four studies, the
clinical significance of the impact of EIAED co-administration on CL was more than 20% [24-26,32]. eGFR was identified to significantly affect the CL of adults with a range of 0.33 to 1.24 times [29] compared to a typical patient with an eGFR of 90 mL/min. ALT was also found to have a significant impact on CL in children, with a range of 0.73 to 1.35 times compared to a typical patient with an ALT level of 30 U/L [33].

Four studies conducted a model-based simulation to show the influence of covariates on the PK profile and optimize the dosage regimen to achieve the target MHD concentrations of 3 and 35 mg/L recommended by the current guideline [29-32]. For adults and paediatric patients, all the four studies recommended adjusting the dosage [29-32]. Chen et al. [31] and Rodrigues et al. [32] had a similar recommended dose range for paediatric patients based on their weight. However, Lin et al. [30] recommended a lower dose than others, which may be explained by the lower CL in their study than others (0.04 L/h/kg vs. 0.059/0.057 L/h/kg). Meanwhile, Rodrigues et al. [32] also recommended increasing the maintenance dose by 50% above the recommended maintenance dose for children treated with EIAEDs.

4. Discussion

To our knowledge, this is the first review that summarised data concerning previously published PPK models of OXC and its active metabolite MHD. We found considerable PK differences between children and adults. We also provided evidence regarding adjustment of the dose regimen according to weight, co-administration with EIAEDs, and eGFR.
The PK of MHD showed no significant differences due to ethnicity. According to the PPK studies, there were similar PK profiles in adults. The weight-standardised CL in Caucasians (median: 0.045, range: 0.029–0.060 L/h/kg) was similar to that in Asians (median: 0.036, range: 0.033–0.039 L/h/kg) (P > 0.05). Likewise, most PPK studies performed in paediatric patients also displayed comparable PK profiles. Moreover, Sugiyama et al. [24] directly compared the PK of MHD among Caucasian, Black, and Asian populations and found no obvious differences among these sub-populations. Nevertheless, studies conducted in Chinese populations showed larger variabilities than other ethnicities (0.016–0.084 L/h/kg vs. 0.043–0.078 L/h/kg). The reason for this is unclear and may require still exploration.

The PK of MHD displayed considerable difference among infant, children, and adult patients. Adults generally displayed lower CL per kg than the infants and children, consistent with the classical PK investigations [38]. This difference may be attributed to the lower body fat/lean mass ratio, higher kidney blood flow, and higher total body water in children [39]. Furthermore, children had a wider weight-standardised CL range than adults, which is attributed to the maturity of the liver and inefficient UGT enzyme capacity [40,41]. A higher CL resulted in a lower concentration of MHD. Therefore, a higher dosage could be used in paediatric patients to achieve the target steady-state concentration of MHD [23].

Recently, OXC was increasingly off-label used to treat epileptic seizures in infants [39] owing to its linear PK, better safety, and well-tolerated profile [6]. Piña-Garza et al. [42] reported that OXC is relatively safe and effective in the treatment of infant
seizures. To date, only one PPK study has been conducted in paediatric patients aged 0.2 to 3.75 years [25]; therefore, clinical data of OXC in the treatment of infants are limited. To ensure better efficacy and safety in infants, further studies are necessary to explore the covariates that affect the variability of OXC.

Previous PPK studies found that EIAEDs could significantly increase the CL of MHD. This is consistent with the PK study performed by McKee et al. [43], who found that CBZ and phenytoin (PHT) decreased the AUC of MHD by 40% and 29%, respectively. As MHD is primarily cleared via glucuronic acid conjugation, EIAEDs may play a more important role through the induction of UGT-mediated glucuronidation to decrease serum MHD concentration [35]. Lower exposure could increase the risk of seizures [44]; therefore, the dose of OXC may be increased when co-administered with EIAEDs.

Renal function may also influence the CL of MHD because OXC and MHD are almost completely excreted by the kidney (94%–97.7%) [5]. Lin et al. [29] found that MHD CL decreased by 64.2% when the eGFR decreased to 20 mL/min and recommended dose adjustment according to eGFR in adult patients. When the eGFR is normal, at approximately 90–120 mL/min, the recommended dose is 225 or 300 mg q12h [29]. When the eGFR is less than 30 mL/min, the recommended dose is 75 mg q12h. This was similar to the OXC label recommendation that indicated that patients with impaired renal function (creatinine clearance <30 mL/min) should initiate OXC at one-half of the dose of 300 mg/day q12h. Therefore, to ensure a safe dose for adults with renal dysfunction, a more detailed dose recommendation may be required.
However, there are also PPK studies that did not identify eGFR as a covariate [24,33]. This may be because of the low proportion of study cohorts with low eGFR levels. Thus, patients with renal impairment on MHD clearance warrant further investigation to optimise their dosing regimen.

There were many unknown variabilities in children that could not be explained by previously reported PPK models. In the included studies, children had a larger RUV (additive model 0.93–5.12 mg/L; proportional model 4%–32%) than adults (RUV: additive model 2.38–3.80 mg/L; proportional model 1.7%–24.5%). Moreover, the practice guideline for the TDM of AEDs indicated the benefits of TDM for children such as diagnosis of clinical toxicity and guide dosage adjustment [45]. Thus, TDM monitoring is more crucial for paediatric patients taking OXC.

5. Conclusions

The PPK studies of OXC have been extensively reviewed. The PK of MHD has a large difference between children and adults. Furthermore, children have a larger variability in PK than adults. This review showed that to optimise the dosing regimen of OXC, the weight, identity of co-administered drugs, and renal function of patients should be considered.

6. Expert Opinion

Long-term maintenance therapy with drugs is one of the important ways of anti-epilepsy. It is high requirements for maintenance dose and dose adjustment, and most antiepileptic drugs have great variability. Therefore, in order to improve the safety and effectiveness, researchers have conducted PPK studies on antiepileptic
drugs, hoping to find the potential covariates that affect its PK variation.

Although, there are many PPK models established, few articles summarised the information of the published PPK studies. This review attempts to summarize the knowledge concerning the PPK modeling of oxcarbazepine to determine the factors that can affect its clearance in the body. We find that there are no significantly difference on races. However, our research shows that children have more variation than adults. Finally, we also explored the significant covariates that may have clinical impact to provide evidence for adjusting dosage regimens of oxcarbazepine.

Owing to the better PK profile and formula diversity, it is increasingly used in the special populations, such as infants and elders. Infants have great variability because of their physiological characteristics and TDM may help to optimize the dosage regimen. However, most hospitals do not realize the importance of TDM monitoring. In the future five years, it is necessary to conduct further studies on infants to find significant covariates that affects their PK variation. Nevertheless, the covariates selected are often different from the theory. This may be due to the smaller variation range of the covariates or the lower proportion of the covariates with large variation range. Therefore, in the future PPK studies, we need to focus on the collection of people with large variation of potential covariates suspected in clinical practice. We maybe get objective and credible results.

In clinical practice, we need to optimize dosing according to PK/PD. PPK studies had shown that the co-administration with inducers can increase the dose of OXC to achieve the therapeutic target concentration. However, there is no corresponding PD
index to determine whether the dose of OXC should be increased in combination with
inducers. Therefore, it is very important to establish PK / PD model to explore the
relationship between dose-exposure-response. Furthermore, we can also use the
established PK / PD model to refine the treatment window in the different disease
severity and population.

6.1 Five-year Review

In order to optimize the clinical administration scheme and reduce the occurrence of
adverse events, PPK modeling was conducted for drugs with large variability and
narrow treatment window. Although many models have been established, there is no
unified standard for the quality of effective identification models. External validation
is the most. In the five future years, it will explore the criteria for evaluating the
quality of models and apply them to evaluate the quality of published models.

The ultimate purpose of establishing PPK model is to solve practical difficulties.
However, the application of PPK models is mainly based on dose simulation. In the
future, exploring meaningful clinical application is one of the main development
directions of PPK study. For instance, the PPK model is used for the remedial
administration of missed late administration. Epilepsy patients are stricter with the
time of taking drugs. Once the occurrence of missing a dose, it is likely to relapse
epilepsy. FDA guidelines for remedial administration of antiepileptic drugs are vague.
Therefore, PPK models plus TDM can be used to give more precise and quantitative
remedy for patients with missed dose. It can minimize the deviation time from the
treatment window and maximize the benefit of patients.
Acknowledgments:

The authors would like to sincerely thank Dr. Vincent Jullien from Service de Pharmacologie, Hôpital européen Georges Pompidou, France; Yang Wang and Jing Peng from Department of Pharmacy, Wuhan Children’s Hospital, China; Yunli Yu from Department of Clinical Pharmacology, The Second Affiliated Hospital of Soochow University, China for providing details about the research and active discussions on the coding. We would like to thank Hai-ni Wen MPharm from Shanghai Chest Hospital; and Ph.D. candidate Xiao-qin Liu from Department of Pharmacy, Huashan Hospital, Fudan University, China for their critical comments. We would also like to thank Editage (www.editage.cn) for English language editing.

Funding: Not applicable.

Declaration of interest

Yue-ting Chen, Chen-yu Wang, Yi-wei Yin, Zi-ran Li, Wei-wei Lin, Min Zhu and Zheng Jiao declare that they have no conflict of interest.

Author contributions

Yue-ting Chen: Data curation, Writing- Original draft preparation, Writing- Reviewing and Editing, Visualization; Chen-yu Wang: Data curation, Writing- Reviewing and Editing; Yi-Wei Yin: Writing- Reviewing and Editing, Supervision; Zi-ran Li: Software, Writing- Reviewing and Editing; Wei-wei Lin: Software, Validation, Writing- Reviewing and Editing; Min Zhu: Software; Zheng Jiao: Conceptualization, Methodology, Writing- Reviewing and Editing, Supervision.


38. Perucca E. Pharmacokinetic variability of new antiepileptic drugs at different


Figure legends

Fig. 1 PRISMA flow diagram for the identification of population pharmacokinetic studies.

Fig. 2 Concentration-time profiles at steady state for (a) infants, (b) children, and (c) adults in retrieved studies.

The solid line represents median of the simulated concentration-time profile. The light shadows represent the 10th-90th percentiles of the simulated concentration-time profiles. The estimated glomerular filtration rate (eGFR) was set to 90 mL/min for adults. The alanine aminotransferase (ALT) for children was set to 30 U/L. Age was set to 18-75 years. All patients were assumed to be male receiving OXC monotherapy at a dose of 300 mg for infants and children; 600 mg for adults.

Fig. 3 Investigated and identified covariates for clearance of oxcarbazepine.

AST: aspartate aminotransferase; ALT: alanine aminotransferase; BSA: body surface area; BMI: body mass index; BUN: blood urea nitrogen; SCr: serum creatinine; eGFR: the estimated glomerular filtration rate; HCT: red blood cell specific volume; HGB: hemoglobin; HT: height; LTG: lamotrigine; LEV: levetiracetam; VPA: co-administration with valproate acid; WT: weight.

Fig. 4 Covariate effect on the clearance of oxcarbazepine.

The horizontal bars represent the covariate effect on clearance in each study. The typical value of clearance in each study was considered to be 1. The effect of each covariate for clearance is displayed by the ratio of clearance in the range of each covariate to the typical clearance value. The shaded gray area ranges from 0.8 to 1.25.

ALT: alanine aminotransferase; eGFR: the estimated glomerular filtration rate; LEV: levetiracetam; LTG: lamotrigine; VPA: co-administration with valproate acid; Y: yes, co-administration; N: no, not co-administration; M: male; F: female.
Table 1 ClinPK checklist of information to be included when reporting a clinical pharmacokinetic study.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Title/abstract</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>100</td>
</tr>
<tr>
<td>drug and patient population</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>100</td>
</tr>
<tr>
<td>name of the drug(s) studied</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>100</td>
</tr>
<tr>
<td>route of administration</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>91.7</td>
</tr>
<tr>
<td>population studied</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>100</td>
</tr>
<tr>
<td>primary objective</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>100</td>
</tr>
<tr>
<td>major findings</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>100</td>
</tr>
<tr>
<td><strong>Background</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>100</td>
</tr>
<tr>
<td>pharmacokinetic data</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>100</td>
</tr>
<tr>
<td>study rationale</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>100</td>
</tr>
<tr>
<td>specific objectives/hypotheses</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>100</td>
</tr>
<tr>
<td><strong>Methods</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>eligibility criteria</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>91.7</td>
</tr>
<tr>
<td>co-administration or food</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>91.7</td>
</tr>
<tr>
<td>dosing</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>83.3</td>
</tr>
<tr>
<td>formulation</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>91.7</td>
</tr>
<tr>
<td>sampling schedule</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>25</td>
</tr>
<tr>
<td>bioanalytical methods</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>83.3</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>----------------------</td>
<td>-------------------</td>
<td>---------------------</td>
<td>-------------------</td>
<td>-------------------</td>
<td>----------------------</td>
<td>------------------</td>
<td>----------------------</td>
<td>----------------------</td>
<td>------------------</td>
<td>------------------</td>
<td>------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>methods for handling missing data</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0</td>
</tr>
<tr>
<td>modeling software</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>100</td>
</tr>
<tr>
<td>statistical methods and software</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>58.3</td>
</tr>
<tr>
<td>candidate structural models</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>75</td>
</tr>
<tr>
<td>residual error structure</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>83.3</td>
</tr>
<tr>
<td>methods for base model determination</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>75</td>
</tr>
<tr>
<td>methods for base model evaluation</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>75</td>
</tr>
<tr>
<td>covariates analysis strategy</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>66.7</td>
</tr>
<tr>
<td>methods for final model evaluation</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>100</td>
</tr>
<tr>
<td>distribution of individual model</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>100</td>
</tr>
<tr>
<td>parameters</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>100</td>
</tr>
<tr>
<td>estimation method(s) used</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>100</td>
</tr>
<tr>
<td>Results</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>100</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-----------------------</td>
<td>-------------------</td>
<td>----------------------</td>
<td>-------------------</td>
<td>-------------------</td>
<td>----------------------</td>
<td>-------------------</td>
<td>---------------------</td>
<td>----------------------</td>
<td>-------------------</td>
<td>-------------------</td>
<td>-------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>schematic of the final model</td>
<td>Green (+)</td>
<td>Red (−)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>91.7</td>
</tr>
<tr>
<td>No. of subjects and observations</td>
<td>Green (+)</td>
<td>Red (−)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>91.7</td>
</tr>
<tr>
<td>table of the final model parameters</td>
<td>Red (−)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>91.7</td>
</tr>
<tr>
<td>final model evaluation plots</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>100</td>
</tr>
<tr>
<td>summary of the model-building process and the derived final model</td>
<td>Green (+)</td>
<td>Red (−)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>91.7</td>
</tr>
<tr>
<td>plot of concentrations vs. time and/or effects vs. concentrations</td>
<td>Green (+)</td>
<td>Red (−)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>Green (+)</td>
<td>91.7</td>
</tr>
</tbody>
</table>

**Discussion/conclusion**

| Study limitations                  | Green (+)             | Red (−)           | Green (+)            | Green (+)         | Green (+)         | Green (+)            | Green (+)         | Green (+)           | Green (+)            | Green (+)         | Green (+)         | Green (+)         | 66.7                |
| Study findings                     | Green (+)             | Green (+)         | Green (+)            | Green (+)         | Green (+)         | Green (+)            | Green (+)         | Green (+)           | Green (+)            | Green (+)         | Green (+)         | Green (+)         | 100                 |

| Compliance rate (%)                | 71.4                  | 71.4              | 68.6                 | 88.6              | 97.1              | 91.4                 | 85.7              | 88.6                | 94.3                 | 88.6              | 94.3              | 94.3              | /                   |
+ Meet report requirements (record 1 score); - Not reported (record zero score);
<table>
<thead>
<tr>
<th>Study (publication year)</th>
<th>Country (type of study)</th>
<th>Number of subjects (Male/Female)</th>
<th>Number of observations</th>
<th>Sampling time</th>
<th>Age(years) Mean ± SD Median [Range]</th>
<th>Weight (kg) Mean ± SD Median [Range]</th>
<th>Formulation</th>
<th>Daily Dose Mean ± SD Median [Range]</th>
<th>Bioassay [LOQ]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Northam et al. (2005)</td>
<td>United States (Prospective)</td>
<td>24 (14/10)</td>
<td>82</td>
<td>SS&lt;sup&gt;d&lt;/sup&gt;</td>
<td>1.7±1.15 [0.2-3.75]</td>
<td>11.3 ± 3.7 [4.7 - 21.8]</td>
<td>NR</td>
<td>Part I: 44.8 [5.3 - 63.2] mg/kg/d</td>
<td>HPLC/LC-MS NR</td>
</tr>
<tr>
<td>Wegner et al. (2013)</td>
<td>Netherlands (Retrospective)</td>
<td>319/464</td>
<td>NR</td>
<td>NR</td>
<td>29.0 [3-80]</td>
<td>62.8 [10.1 - 95.0]</td>
<td>NR</td>
<td>tablets</td>
<td>HPLC [0.1 mg/L]</td>
</tr>
<tr>
<td>Park et al. (2012)</td>
<td>Korea (Retrospective)</td>
<td>209 (97/112)</td>
<td>254</td>
<td>NR</td>
<td>7.37±3.6 [0.2-18]</td>
<td>27.64 ± 12.93 [4 - 90]</td>
<td>tablets</td>
<td>[945.19 ± 469.84 mg/d</td>
<td>HPLC NR</td>
</tr>
<tr>
<td>Wang et al. (2014)</td>
<td>China (Retrospective)</td>
<td>573 (365/208)</td>
<td>1031</td>
<td>NR</td>
<td>7.39 [0.58 - 17]</td>
<td>27.5 ± 6.5</td>
<td>tablets</td>
<td>[75 - 1350] mg/d</td>
<td>HPLC [0.4 mg/L]</td>
</tr>
<tr>
<td>Peng et al. (2014)</td>
<td>China (Retrospective)</td>
<td>466 (300/166)</td>
<td>840</td>
<td>SS&lt;sup&gt;e&lt;/sup&gt;</td>
<td>37±21</td>
<td>43.3 ± 20.7</td>
<td>tablets</td>
<td>[300 – 2100] mg/d</td>
<td>HPLC [0.393 mmol/L]</td>
</tr>
<tr>
<td>Sugiyama et al. (2015)</td>
<td>multicenter&lt;sup&gt;a&lt;/sup&gt;</td>
<td>109 (58/51)</td>
<td>376</td>
<td>SS&lt;sup&gt;d&lt;/sup&gt;</td>
<td>11.0±3.9</td>
<td>43.3 ± 20.7</td>
<td>tablets</td>
<td>[312 – 1800] mg/d</td>
<td>LC-MS/MS [0.1 mmol/L]</td>
</tr>
<tr>
<td>Yu et al. (2016)</td>
<td>China (Retrospective)</td>
<td>78 (54/24)</td>
<td>108</td>
<td>SS&lt;sup&gt;f&lt;/sup&gt;</td>
<td>37±21</td>
<td>23 [12.7 - 56]</td>
<td>tablets</td>
<td>[300 – 1350] mg/d</td>
<td>HPLC [0.4 mg/L]</td>
</tr>
<tr>
<td>Antunes et al. (2017)</td>
<td>Brazil (Prospective)</td>
<td>12 (4/8)</td>
<td>185</td>
<td>IS&lt;sup&gt;i&lt;/sup&gt;</td>
<td>29.50 [22.00–41.00]</td>
<td>61.75 [48.70 -95.15]</td>
<td>tablets</td>
<td>600 mg/d</td>
<td>LC-MS/MS [0.02 mg/L]</td>
</tr>
<tr>
<td>Rodrigues et al. (2017)</td>
<td>France (Prospective)</td>
<td>31 (18/13)</td>
<td>556</td>
<td>IS&lt;sup&gt;j&lt;/sup&gt;</td>
<td>8.08 [2.25 - 12.5]</td>
<td>23 [12.7 - 56]</td>
<td>tablets or suspension</td>
<td>5 or 15 mg/kg/d</td>
<td>HPLC [0.05 mg/L]</td>
</tr>
<tr>
<td>Chen et al. (2019)</td>
<td>China (Retrospective)</td>
<td>88 (38/50)</td>
<td>91</td>
<td>NR</td>
<td>4.00 [0.17 -15.00]</td>
<td>18.50 [5.25 - 66.30]</td>
<td>suspension</td>
<td>26.09 [7.5 - 54.0] mg/kg/d</td>
<td>HPLC [2mg/L]</td>
</tr>
<tr>
<td>Lin et al. (2019)</td>
<td>China (Prospective)</td>
<td>141 (90/51)</td>
<td>301</td>
<td>C&lt;sub&gt;in&lt;/sub&gt;</td>
<td>7.97 ± 3.36 [0.50-14.00]</td>
<td>29.71 ± 12.98 [5.9 - 72.3]</td>
<td>tablets or suspension</td>
<td>618.58 ± 208.23 mg/d</td>
<td>EMIT [1.0 mg/L]</td>
</tr>
<tr>
<td>Study (publication year)</td>
<td>Country (type of study)</td>
<td>Number of subjects (Male/Female)</td>
<td>Number of observations</td>
<td>Sampling time</td>
<td>Age (years) Mean ± SD Median [Range]</td>
<td>Weight (kg) Mean ± SD Median [Range]</td>
<td>Formulation</td>
<td>Daily Dose Mean ± SD Median [Range]</td>
<td>Bioassay [LOQ]</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-------------------------</td>
<td>---------------------------------</td>
<td>------------------------</td>
<td>--------------</td>
<td>------------------------------------</td>
<td>------------------------------------</td>
<td>-------------</td>
<td>----------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Lin et al. (2019)</td>
<td>China (Prospective)</td>
<td>187 (131/56)</td>
<td>316</td>
<td>C\textsubscript{trough}</td>
<td>37.1 ± 16.1 [18.0 - 90.0]</td>
<td>62.0 ± 10.8 [37.0 - 95.5]</td>
<td>tablets</td>
<td>759 ± 244 [450 - 2700] mg/d</td>
<td>EMIT [1.0 mg/L]</td>
</tr>
</tbody>
</table>

\(C\textsubscript{trough}: \) trough concentration; \(EMIT: \) enzyme multiplied immunoassay technique; \(HPLC: \) high-performance liquid; \(IS: \) Intensive sampling; \(LC-MS/MS: \) liquid chromatograph mass spectrometer or mass spectrometer; \(LOQ: \) lower limits of quantification; \(MHD: \) monohydroxycarbazepine; \(NR: \) not reported; \(OXC: \) oxcarbazepine; \(SS: \) sparse sampling.

\(^1\)multicenter: Argentina, Chile, Uruguay, Australia, New Zealand, Canada, Israel, and the United States.

\(^2\)SS: 0 (pre-dose), 0.5, 2, 5-8 h post-dose.

\(^3\)SS: 0-48 h after dose;

\(^4\)SS: at least 1 sample in each of the following intervals: 8 to 11 AM, 11:01 AM to 2 PM, and 2:01 to 6 PM.

\(^5\)SS: Sample 1: trough (about 12 h after the last dose), Sample 2: approximately Tmax (about 4-6 h after administration), Sample 3: initial (around 30 min to 2 h after administration), Sample 4: trough (at another visit than that for the trough sample 1).

\(^6\)SS: 0.5–8 h of the dosing interval and \(C\textsubscript{trough}\).

\(^7\)IS: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10 and 12 h post dose.

\(^8\)IS: Part I: 1, 2, 4, 6, 8, 12, 24, 36, and 48 hours post dose.

\(^9\)Part I: treatment phase.

\(^{10}\)Part II: extension phases.
<table>
<thead>
<tr>
<th>Study (publication year)</th>
<th>Software / Algorithm</th>
<th>Fixed effect parameters</th>
<th>Between-subject variability (%)</th>
<th>residual unexplained variability</th>
<th>Internal validation</th>
<th>External validation (N=number of subjects)</th>
<th>Model application</th>
</tr>
</thead>
<tbody>
<tr>
<td>Northam et al. (2005)</td>
<td>NONMEM / FO</td>
<td>$K_a$ 0.598 2.18 × (BSA/1.3) $^{1.1}$ × 1.27 (if co-CBZ) × 1.27 (if co-PB) × 1.63 (if co-PHT) 50.5 × (HT/145) $^{1.96}$</td>
<td>4.9 1.8</td>
<td>3.79 mg/L 0.2%</td>
<td>GOF NR</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Park et al. (2012)</td>
<td>NONMEM / FOCE-I</td>
<td>$K_a$ 0.598 2.13 × (WT/62.8) $^{0.666}$ × 0.312 (if co-EIAEDs) 49</td>
<td>/ 23.9%</td>
<td>2.83 mg/L</td>
<td>GOF NR</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Wegner et al. (2013)</td>
<td>NONMEM / FOCE-I</td>
<td>$K_a$ 1 4.66 × (WT/70) $^{0.362}$ × (Age/32.8) $^{0.532}$ 80</td>
<td>29 9%</td>
<td>/ 3.8 mg/L</td>
<td>Bootstrap NR</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Wang et al. (2014)</td>
<td>Phoenix NLME / FOCE-L-B</td>
<td>$K_a$ 0.83 0.035 × WT × 1.11 (if co-new-AEDs) × 0.97 (if co-VPA) × 1.17 (if co-EIAEDs) 0.67×WT</td>
<td>39.82 6.89</td>
<td>0.93 mg/L</td>
<td>Bootstrap, GOF</td>
<td>N=115</td>
<td>NR</td>
</tr>
<tr>
<td>Peng et al. (2014)</td>
<td>Phoenix NLME / FOCE</td>
<td>$K_a$ 0.6454 0.5570 + (Dose/WT – 20.8) × 0.003673 - 0.06365 (if female)</td>
<td>/ 19.41</td>
<td>/</td>
<td>GOF, NR</td>
<td>VPC, bootstrap,</td>
<td></td>
</tr>
<tr>
<td>Sugiyama et al. (2015)</td>
<td>NONMEM / FOCE</td>
<td>$K_a$ 0.406 11.33 + (Age – 7.5) × 0.02818 × (WT– 25) × 0.4022</td>
<td>6.9</td>
<td>/ 18.3%</td>
<td>VPC, GOF</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Yu et al. (2016)</td>
<td>Phoenix NLME / FOCE-ELS</td>
<td>$K_a$ 0.0833 0.0904 × Age $^{-0.1444}$ 2.38 × (ALT/30) $^{0.181}$ × 1.083 (if female) 14.2 × (BUN/4.76) $^{(-0.007)}$ × (HGB/140) $^{(-0.001)}$</td>
<td>8.3 157.8</td>
<td>NR</td>
<td>Bootstrap, VPC, MHD: 9.7% OXC: 9.7%</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Antunes et al. (2017)</td>
<td>NONMEM / FOCE</td>
<td>$V_{MH-D}$ 2.01 × (WT/68)$^{0.75}$ 23.6× (WT/68) $^{2.36}$ 31.7× (WT/68)</td>
<td>9.7 1.7</td>
<td>104.4</td>
<td>VPC, NPDE, GOF, PPC</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Study (publication year)</td>
<td>Software / Algorithm</td>
<td>Fixed effect parameters</td>
<td>Between-subject variability (%)</td>
<td>residual unexplained variability</td>
<td>Internal validation</td>
<td>External validation (N=number of samples)</td>
<td>Model application</td>
</tr>
<tr>
<td>-------------------------</td>
<td>----------------------</td>
<td>-------------------------</td>
<td>-------------------------------</td>
<td>-------------------------------</td>
<td>-------------------</td>
<td>------------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Rodrigues et al. (2017)</td>
<td>Monolix / SAEM</td>
<td>$K_a$, $C_{LOXC}$, $V_{C_{-OXC}}$, $Q_{OX}$</td>
<td>/</td>
<td>39.3</td>
<td>MHD: 0.993mg/L</td>
<td>OXC: 32% VPC, NPDE, GOF</td>
<td>NR, design dosage</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$V_p_{-OXC}$, $CL_{MHD}$, $V_{C_{-MHD}}$</td>
<td>337 × (WT/70) $^{2.4}$</td>
<td>60.1</td>
<td>4.0%</td>
<td></td>
<td>regime</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KBT</td>
<td>0.0622</td>
<td>126</td>
<td>23.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>54.8 × (WT/70) $^{1.09}$</td>
<td>21.1</td>
<td>63</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen et al. (2019)</td>
<td>NONMEM / FOCE-I</td>
<td>$K_a$, $CL$, $V$</td>
<td>/</td>
<td>34.2</td>
<td>5.12mg/L</td>
<td>Bootstrap, N=10 GOF, NPDE</td>
<td>design dosage</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3.25 × (WT/70) $^{0.75}$</td>
<td>1.68 × (WT/70) $^{0.624-0.233\times WT^{219}8.97^{219}\times WT^{219}}$</td>
<td>2.992mg/L</td>
<td></td>
<td>regime</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>151.41 × (WT/70)</td>
<td>/</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lin et al. (2019)</td>
<td>NONMEM / FOCE-I</td>
<td>$K_a$, $CL$, $V$</td>
<td>/</td>
<td>11.1</td>
<td>2.992mg/L</td>
<td>GOF, bootstrap</td>
<td>NR, design dosage</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.83</td>
<td>14.7</td>
<td>/</td>
<td></td>
<td>regime</td>
</tr>
<tr>
<td>Lin et al. (2019)</td>
<td>NONMEM / FOCE-I</td>
<td>$K_a$, $CL$, $V$</td>
<td>/</td>
<td>12.7</td>
<td>24.5%</td>
<td>GOF, Bootstrap</td>
<td>NR, design dosage</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.46</td>
<td>102</td>
<td>12.7</td>
<td></td>
<td>regime</td>
</tr>
</tbody>
</table>

ALT: alanine aminotransferase (U/L); BUN: blood urea nitrogen (mmol/L); BSA: body surface area (m²); CBZ: carbamazepine; CL: apparent clearance (L/h); CL_{OXC}: the apparent elimination clearances of OXC (L/h); COR: covariance between CL and V; co-X: co-administration with medications; eGFR: the estimated glomerular filtration rate (ml/min); EIAEDs: Enzyme-inducing antiepileptic drug; F: bioavailability; FOCE: first order conditional estimation; FOCE-I: first-order conditional estimation with the interaction; FOCE ELS: first-order conditional estimation method with the η-ε interaction option; FOCE L-B: first-order conditional estimation method with the η-ε interaction option; GOF: goodness-of-fit plot; $K_a$: absorption rate constant (h⁻¹); HGB: hemoglobin (g/L); HT: height (cm); KBT: the back-transformation constant rate of MHD into OXC (h⁻¹); NR: not reported; new-AEDs: newer antiepileptic drug such as levetiracetam, lamotrigine; NPDE: normalized prediction distribution errors; PB: phenobarbital; PHT: phenytoin; PPC: posterior predictive check; Q_{OX}: the apparent distribution clearances of OXC; SAEM: stochastic approximation expectation maximization; Tlag: absorption lag time (h); $V_{C_{-OXC}}$: the apparent central distribution volumes of OXC (L); Vd: apparent volume of distribution (L); $V_{P_{-OXC}}$: the apparent peripheral distribution volumes of OXC (L); VPA: valproic acid; VPC: visual predictive check. WT: Weight (kg);